Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2033 Filed Mar 21, 2023 23:54 UTC |
Lee Phillip EChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007441 · rdgdoc.xml · derivative · entry 5 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2033-03-16 F4 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
BREITMEYER JAMES BDirector
|
GrantStock Options (right to buy) · Derivative | 16,610 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023810 · rdgdoc.xml · derivative · entry 2 BREITMEYER JAMES B · CIK 0001244823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,610 Underlying: Common Stock · 16,610 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
BREITMEYER JAMES BDirector
|
GrantCommon Stock | 8,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023810 · rdgdoc.xml · nonDerivative · entry 1 BREITMEYER JAMES B · CIK 0001244823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,115 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
HERON ELAINE JDirector
|
GrantStock Options (right to buy) · Derivative | 78,700 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023809 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,700 Underlying: Common Stock · 78,700 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
HERON ELAINE JDirector
|
GrantCommon Stock | 39,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023809 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,966 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
Watson W. MarkDirector
|
GrantStock Options (right to buy) · Derivative | 78,700 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023808 · rdgdoc.xml · derivative · entry 2 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,700 Underlying: Common Stock · 78,700 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
Watson W. MarkDirector
|
GrantCommon Stock | 39,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023808 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,525 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
Wheadon David E.Director
|
GrantStock Options (right to buy) · Derivative | 78,700 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023807 · rdgdoc.xml · derivative · entry 2 Wheadon David E. · CIK 0001789507 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,700 Underlying: Common Stock · 78,700 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC |
Wheadon David E.Director
|
GrantCommon Stock | 39,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023807 · rdgdoc.xml · nonDerivative · entry 1 Wheadon David E. · CIK 0001789507 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,150 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:04 UTC |
Finney KevinDirector
|
GrantStock Options (right to buy) · Derivative | 78,700 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023863 · rdgdoc.xml · derivative · entry 2 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,700 Underlying: Common Stock · 78,700 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:04 UTC |
Finney KevinDirector
|
GrantCommon Stock | 39,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023863 · rdgdoc.xml · nonDerivative · entry 1 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,171 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| May 22, 2026 Filed May 26, 2026 21:11 UTC |
Watson W. MarkDirector
|
PurchaseCommon Stock | 10,000 | $0.65 | $6,530.00 |
DisclosureSEC source: 0001437749-26-018385 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,125 Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:13 UTC |
Grasman Jeroen NicolaasChief Financial Officer
|
Tax withholdingCommon Stock | 31,395 | $0.61 | $19,150.95 |
DisclosureSEC source: 0001437749-26-018117 · rdgdoc.xml · nonDerivative · entry 1 Grasman Jeroen Nicolaas · CIK 0002067766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,605 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of May 19, 2026. Read SEC document |
| April 23, 2026 Filed May 2, 2026 00:55 UTC |
BREITMEYER JAMES BDirector
|
GrantStock Option (right to buy) · Derivative | 157,400 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001437749-26-014528 · rdgdoc.xml · derivative · entry 2 BREITMEYER JAMES B · CIK 0001244823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,400 Underlying: Common Stock · 157,400 shares Expires 2036-04-23 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board. Read SEC document |
| April 23, 2026 Filed May 2, 2026 00:55 UTC |
BREITMEYER JAMES BDirector
|
GrantCommon Stock | 78,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-014528 · rdgdoc.xml · nonDerivative · entry 1 BREITMEYER JAMES B · CIK 0001244823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,800 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board of Directors (the "Board"). Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:44 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 3,924 | $0.65 | $2,550.60 |
DisclosureSEC source: 0001437749-26-010709 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882,811 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:44 UTC |
Cummings James F.Chief Medical Officer
|
Tax withholdingCommon Stock | 3,292 | $0.65 | $2,139.80 |
DisclosureSEC source: 0001437749-26-010707 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 924,177 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:52 UTC |
Berg Edward BSVP, General Counsel
|
Tax withholdingCommon Stock | 36,418 | $0.69 | $25,274.09 |
DisclosureSEC source: 0001437749-26-009969 · rdgdoc.xml · nonDerivative · entry 1 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,368 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. F2 · balance_after: This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:52 UTC |
Cummings James F.Chief Medical Officer
|
Tax withholdingCommon Stock | 30,551 | $0.69 | $21,202.39 |
DisclosureSEC source: 0001437749-26-009968 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,469 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:52 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
Tax withholdingCommon Stock | 126,028 | $0.69 | $87,463.43 |
DisclosureSEC source: 0001437749-26-009967 · rdgdoc.xml · nonDerivative · entry 1 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,485,606 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:51 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 36,418 | $0.69 | $25,274.09 |
DisclosureSEC source: 0001437749-26-009966 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,735 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:16 UTC |
Berg Edward BSVP, General Counsel
|
Tax withholdingCommon Stock | 8,072 | $0.63 | $5,122.49 |
DisclosureSEC source: 0001437749-26-009208 · rdgdoc.xml · nonDerivative · entry 1 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,786 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. F2 · balance_after: This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:15 UTC |
Cummings James F.Chief Medical Officer
|
Tax withholdingCommon Stock | 6,772 | $0.63 | $4,297.51 |
DisclosureSEC source: 0001437749-26-009207 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958,020 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:15 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
Tax withholdingCommon Stock | 22,425 | $0.63 | $14,230.91 |
DisclosureSEC source: 0001437749-26-009206 · rdgdoc.xml · nonDerivative · entry 1 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,611,634 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:14 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 8,072 | $0.63 | $5,122.49 |
DisclosureSEC source: 0001437749-26-009205 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,153 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 01:44 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
GrantStock Option (right to buy) · Derivative | 1,543,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008925 · rdgdoc.xml · derivative · entry 3 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,543,000 Underlying: Common Stock · 1,543,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 01:44 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
GrantCommon Stock | 846,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008925 · rdgdoc.xml · nonDerivative · entry 1 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,634,059 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008909 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008909 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931,225 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC |
Grasman Jeroen NicolaasChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 455,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008908 · rdgdoc.xml · derivative · entry 2 Grasman Jeroen Nicolaas · CIK 0002067766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC |
Grasman Jeroen NicolaasChief Financial Officer
|
GrantCommon Stock | 227,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008908 · rdgdoc.xml · nonDerivative · entry 1 Grasman Jeroen Nicolaas · CIK 0002067766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,000 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC |
Cummings James F.Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 455,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008907 · rdgdoc.xml · derivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC |
Cummings James F.Chief Medical Officer
|
GrantCommon Stock | 227,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008907 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,792 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC |
Berg Edward BSVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008906 · rdgdoc.xml · derivative · entry 2 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:41 UTC |
Berg Edward BSVP, General Counsel
|
GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008906 · rdgdoc.xml · nonDerivative · entry 1 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 799,858 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 23:54 UTC |
Cummings James F.Chief Medical Officer
|
Tax withholdingCommon Stock | 7,965 | $0.61 | $4,846.70 |
DisclosureSEC source: 0001437749-26-003255 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,792 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. F2 · balance_after: This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 23:53 UTC |
Berg Edward BSVP, General Counsel
|
Tax withholdingCommon Stock | 9,265 | $0.61 | $5,637.75 |
DisclosureSEC source: 0001437749-26-003254 · rdgdoc.xml · nonDerivative · entry 1 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 684,858 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. F2 · balance_after: This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 23:53 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 9,265 | $0.61 | $5,637.75 |
DisclosureSEC source: 0001437749-26-003253 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,225 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 02:43 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
Tax withholdingCommon Stock | 54,153 | $0.37 | $20,036.61 |
DisclosureSEC source: 0001437749-25-037206 · rdgdoc.xml · nonDerivative · entry 2 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,787,559 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 4, 2025. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 02:43 UTC |
Lo StevenDirector · President, Chief Exec Officer
|
GrantCommon Stock | 151,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037206 · rdgdoc.xml · nonDerivative · entry 1 Lo Steven · CIK 0001501959 · Director · President, Chief Exec Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,841,712 F1 · shares: Grant of shares upon vesting of restricted stock units, which fully vested on December 4, 2025. F2 · balance_after: This amount includes 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Read SEC document |
| November 17, 2025 Filed Nov 21, 2025 18:21 UTC |
HERON ELAINE JDirector
|
PurchaseCommon Stock | 16,783 | $0.41 | $6,797.12 |
DisclosureSEC source: 0001437749-25-035952 · rdgdoc.xml · nonDerivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,566 Read SEC document |
| November 17, 2025 Filed Nov 21, 2025 18:21 UTC |
HERON ELAINE JDirector
|
PurchaseCommon Stock | 23,217 | $0.39 | $9,124.28 |
DisclosureSEC source: 0001437749-25-035952 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,783 Read SEC document |
| November 17, 2025 Filed Dec 5, 2025 22:46 UTC |
Watson W. MarkDirector
|
PurchaseCommon Stock | 5,000 | $0.41 | $2,035.00 |
DisclosureSEC source: 0001437749-25-037051 · rdgdoc.xml · nonDerivative · entry 2 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,125 F1 · date: This Form 4 is being filed late due to delays in receiving EDGAR access codes. Read SEC document |
| November 17, 2025 Filed Dec 5, 2025 22:46 UTC |
Watson W. MarkDirector
|
PurchaseCommon Stock | 15,000 | $0.41 | $6,150.00 |
DisclosureSEC source: 0001437749-25-037051 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,125 F1 · date: This Form 4 is being filed late due to delays in receiving EDGAR access codes. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC |
Finney KevinDirector
|
PurchaseCommon Stock | 50,000 | $0.37 | $18,500.00 |
DisclosureSEC source: 0001437749-25-027356 · rdgdoc.xml · nonDerivative · entry 6 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,771 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC |
Finney KevinDirector
|
PurchaseCommon Stock | 50,000 | $0.35 | $17,500.00 |
DisclosureSEC source: 0001437749-25-027356 · rdgdoc.xml · nonDerivative · entry 5 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,771 Read SEC document |
| July 30, 2025 Filed Aug 19, 2025 20:06 UTC |
Finney KevinDirector
|
PurchaseCommon Stock | 25,874 | $0.38 | $9,832.12 |
DisclosureSEC source: 0001437749-25-027356 · rdgdoc.xml · nonDerivative · entry 4 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,771 F1 · date: This transaction is being reported late due to an administrative oversight. Read SEC document |
| July 29, 2025 Filed Aug 1, 2025 00:38 UTC |
Watson W. MarkDirector
|
PurchaseCommon Stock | 10,000 | $0.41 | $4,050.00 |
DisclosureSEC source: 0001437749-25-024250 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,125 Read SEC document |
| July 28, 2025 Filed Aug 19, 2025 20:06 UTC |
Finney KevinDirector
|
PurchaseCommon Stock | 20,000 | $0.40 | $8,000.00 |
DisclosureSEC source: 0001437749-25-027356 · rdgdoc.xml · nonDerivative · entry 3 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,897 F1 · date: This transaction is being reported late due to an administrative oversight. Read SEC document |
| July 25, 2025 Filed Aug 19, 2025 20:06 UTC |
Finney KevinDirector
|
PurchaseCommon Stock | 20,000 | $0.39 | $7,800.00 |
DisclosureSEC source: 0001437749-25-027356 · rdgdoc.xml · nonDerivative · entry 2 Finney Kevin · CIK 0002053381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,897 F1 · date: This transaction is being reported late due to an administrative oversight. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.